Welcome to our dedicated page for Upexi SEC filings (Ticker: UPXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Upexi’s filings can feel like a puzzle—hemp wellness, nutraceutical pills, pet treats, Disney-licensed toys, even crypto mining all live under one roof. Locating segment revenue or the impact of Amazon fees means combing through thousands of lines. If you have ever typed “Upexi insider trading Form 4 transactions” into Google, you already know the challenge.
Stock Titan’s platform turns that maze into a map. Our AI reads every Upexi quarterly earnings report 10-Q filing, flags revenue swings, and highlights inventory write-downs. Need real-time alerts? We stream Upexi Form 4 insider transactions real-time, so you spot executive buys and sells faster. From concise dashboards to one-click downloads, this page delivers Upexi SEC filings explained simply—covering 10-K annual reports, 8-K event notices, and proxy statements that detail executive compensation.
Use cases are immediate: compare hemp gross margins quarter over quarter, monitor Upexi executive stock transactions Form 4 before material events, or trace how restructuring shows up in an Upexi 8-K material events explained alert. Our AI summaries shave hours off Upexi earnings report filing analysis while understanding Upexi SEC documents with AI keeps jargon in check. Whether you want an Upexi annual report 10-K simplified or to review an Upexi proxy statement executive compensation table, every document arrives seconds after EDGAR posts. No more hunting—just the insights that matter across one diversified consumer powerhouse.
UPXI (S-1/A) amendment discloses multiple operational, financing and asset items. The company relocated manufacturing from Nevada to Florida and occupies a new Tampa warehouse and headquarters lease, recording $611,768 in leasehold improvements and moving production to full capacity as of August 1, 2024. The company sold a building for $4,300,000 (closing July 8, 2024). It recorded significant non-cash charges: an $4,274,680 impairment of intangible assets (including $3,300,000 for Cygnet vendor list and $974,680 for LuckyTail customer decline) and recorded goodwill eliminations of $3,594,745. Valuation allowances rose to $6,100,000 (June 30, 2024) and $7,791,500 (March 31, 2025). Bad debt expense and reserves increased materially (e.g., $773,915 bad debt for nine months ended March 31, 2025 and accounts receivable reserve $591,600 at March 31, 2025). Financing activity includes amended promissory notes with investor amendments, convertible notes/warrants and a private placement netting approximately $92,586,000. The filing records a dispute over ~202,183 shares related to a reverse split and potential dilution being litigated in federal court.
Upexi, Inc. amended its S-1 registration and disclosed several material operational and financial developments. The company leased warehouse and office space in Tampa, Florida for distribution and corporate headquarters. It sold a building for $4,300,000 and completed a move of product manufacturing to Florida by August 1, 2024. The company recorded an $4,274,680 impairment of intangible assets and eliminated goodwill related to acquisitions totaling $3,594,745 and $2,889,158 in prior periods. Inventory reserves increased to $803,073 at March 31, 2025 and bad debt expense rose to $773,915 for the three months ended March 31, 2025. The firm reported a $6,100,000 valuation allowance and described several amended promissory notes and convertible financings, including warrants and debt restructurings. The company received approximately $92,586,000 net from a private placement.
Upexi, Inc. amended its S-1 registration and disclosed multiple operational, financing and restructuring items. The company recorded significant intangible impairments of $4,274,680 in fiscal 2024, including $974,680 related to LuckyTail and $3,300,000 related to Cygnet vendor lists. A $6,100,000 valuation allowance was recorded at June 30, 2024, rising to $7,791,500 at March 31, 2025. Inventory reserves increased to $803,073 at March 31, 2025 from $605,470 at June 30, 2024. The company sold a building for $4,300,000 on July 8, 2024 and moved manufacturing from Nevada to Florida, completing the move by August 1, 2024.
The company disclosed multiple debt amendments and financings, including amended promissory notes with related warrants, a $1,500,000 Marshall loan with 8.5% cash interest plus 3.5% PIK, and convertible notes originally $7,500,000 with related warrants. The reverse stock split and issuance/return of 202,183 shares to DTC created a pending dilution dispute in federal court.
Upexi, Inc. (UPXI) amended its S-1 filing and disclosed multiple operational and financial changes. The company moved manufacturing from Nevada to Florida, leased warehouse and office space in Tampa, and sold a building for $4,300,000. It recognized significant non-cash charges including a $4,274,680 impairment of intangible assets (split: $974,680 related to LuckyTail and $3,300,000 related to Cygnet vendor lists) and recorded goodwill eliminations of $3,594,745 (Cygnet) and $2,889,158 (Interactive Offers).
Liquidity and credit matters are highlighted: management recorded valuation allowances of $6,100,000 at June 30, 2024 and $7,791,500 at March 31, 2025, increased inventory reserves to $803,073 at March 31, 2025, and reported elevated bad debt expense (e.g., $773,915 for the three months ended March 31, 2025). The company amended multiple promissory notes (interest-only periods at 12% with later amortization) and received a bank forbearance tied to a debt service ratio covenant. The company also disclosed potential dilution and related litigation after issuance and return of 202,183 common shares following a reverse stock split.
Upexi, Inc. amended its S-1 registration and disclosed material operational and financings developments. The company relocated manufacturing to Florida and leased new warehouse and headquarters space in Tampa. It sold a building for $4.3 million and completed a move of product manufacturing to full capacity as of August 1, 2024. The company recorded significant non-cash charges including an $4,274,680 impairment of intangible assets and recognized goodwill write-offs tied to acquisitions. Inventory reserves and bad debt expense increased materially, with a valuation allowance of $6,100,000 at June 30, 2024 rising to $7,791,500 at March 31, 2025. Debt arrangements were amended, including promissory notes with interest-only periods at 12% per annum and other financings; convertible securities and warrants remain outstanding. The company reported discontinued operations from the sale of VitaMedica and cited a potential dilution issue from reverse-split share rounding that is the subject of litigation.
FAQ
What is the current stock price of Upexi (UPXI)?
What is the market cap of Upexi (UPXI)?
